MAPT and Alzheimer disease: composed magnetic mesoporous silica nanoparticles (M‐MSN) that are functionalized with ceria nanoparticles (CNPs) and anti‐tau antibodies (AT8) as a potential therapeutic for AD.[134] In vitro studies showed the potential for CNPs to promote autophagy and prevent pathogenic tau accumulation.